Jun 27 |
Oculis and EURETINA Announces the Ramin Tadayoni Award
|
Jun 11 |
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
|
Jun 10 |
Oculis sees promising topline phase 2 results for licaminlimab for dry eye
|
Jun 10 |
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
|
May 30 |
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
|
May 23 |
While institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownership
|
May 9 |
Oculis Holding reports Q1 results
|
May 8 |
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
|
May 8 |
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
|
Apr 29 |
Oculis Publishes Invitation to the Annual General Meeting
|